Wednesday - October 23, 2024
Novo Nordisk Enters NanoVation Therapeutics Partnership to Develop Genetic Medicines Targeting Rare, Cardiometabolic Diseases
October 05, 2024
BOSTON, Massachusetts, Oct. 5 -- Ropes and Gray, a law firm, issued the following news:

Ropes & Gray advised Novo Nordisk in a multi-year partnership with NanoVation Therapeutics to develop genetic medicines for rare and cardiometabolic diseases.

Novo Nordisk will receive an exclusive worldwide license to use NanoVation's long-circulating lipid nanoparticle technology for RNA delivery targeting cells outside the liver. The partnership was announced on September 18.< . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products